A Look At Exelixis (EXEL) Valuation After Zanzalintinib Phase 3 Success And New STELLAR-316 Trial

Simply Wall St.01-10

Exelixis (EXEL) is back in focus after reporting strong phase 3 data for zanzalintinib in metastatic colorectal cancer, alongside launching the Natera partnership for the planned STELLAR-316 pivotal ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602530713?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/28338-main-header/1585188087119","is_english":true,"pubTime":"2026-01-10 06:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602530713","market":"hk","top_or_hot":-1,"title":"A Look At Exelixis (EXEL) Valuation After Zanzalintinib Phase 3 Success And New STELLAR-316 Trial","media":"Simply Wall St.","content":"<div>\n<p>Exelixis (EXEL) is back in focus after reporting strong phase 3 data for zanzalintinib in metastatic colorectal cancer, alongside launching the Natera partnership for the planned STELLAR-316 pivotal ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/a-look-at-exelixis-exel-valuation-after-zanzalintinib-phase\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Exelixis (EXEL) Valuation After Zanzalintinib Phase 3 Success And New STELLAR-316 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Exelixis (EXEL) Valuation After Zanzalintinib Phase 3 Success And New STELLAR-316 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-10 06:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/a-look-at-exelixis-exel-valuation-after-zanzalintinib-phase><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Exelixis (EXEL) is back in focus after reporting strong phase 3 data for zanzalintinib in metastatic colorectal cancer, alongside launching the Natera partnership for the planned STELLAR-316 pivotal ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/a-look-at-exelixis-exel-valuation-after-zanzalintinib-phase\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/a-look-at-exelixis-exel-valuation-after-zanzalintinib-phase","article_id":"2602530713","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/28338-main-header/1585188087119"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exel/exelixis/news/a-look-at-exelixis-exel-valuation-after-zanzalintinib-phase","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602530713","pubTimestamp":1767997690,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Exelixis (EXEL) is back in focus after reporting strong phase 3 data for zanzalintinib in metastatic colorectal cancer, alongside launching the Natera partnership for the planned STELLAR-316 pivotal trial in earlier stage disease.\nSee our latest analysis for Exelixis.\nThe recent phase 3 readout for zanzalintinib and the planned STELLAR-316 trial come after a strong run in the shares, with a 90 day share price return of 15.44% and a 1 year total shareholder return of 22.27%. The 3 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4532":"文艺复兴科技持仓","EXEL":"伊克力西斯"},"translate_title":"赞扎林替尼3期成功和新的STELLAR-316试验后Exelixis(EXEL)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXEL":1.5},"content_text":"Exelixis (EXEL) is back in focus after reporting strong phase 3 data for zanzalintinib in metastatic colorectal cancer, alongside launching the Natera partnership for the planned STELLAR-316 pivotal trial in earlier stage disease. See our latest analysis for Exelixis. The recent phase 3 readout for zanzalintinib and the planned STELLAR-316 trial come after a strong run in the shares, with a 90 day share price return of 15.44% and a 1 year total shareholder return of 22.27%. The 3 year total shareholder return of 168.05% suggests momentum has been building over a longer period. If Exelixis' cancer pipeline has your attention, this could be a good moment to widen your watchlist to other healthcare stocks pursuing new therapies. With the shares already up strongly over 1 year and trading only about 3% below the average analyst target, the key question now is simple: is Exelixis still underappreciated, or is the market already pricing in its future growth? AdvertisementMost Popular Narrative: 2.1% Undervalued Compared with Exelixis' last close of US$44.04, the most followed narrative sets fair value slightly higher, suggesting only a modest gap to intrinsic worth.  The company's substantial free cash flow, strong balance sheet, and disciplined capital allocation (including aggressive share repurchases and prioritization of high-probability, high-value R&D programs) position Exelixis to invest in next-generation discovery and strategic partnerships, which has the potential to improve operating leverage and net margins over time as the product portfolio scales.  Read the complete narrative. Curious how steady double digit growth, rising profitability, and a lower future earnings multiple all fit together into that fair value? The full narrative unpacks the exact revenue path, margin profile, and valuation multiple it uses to justify this outlook. Result: Fair Value of $45 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the heavy dependence on cabozantinib, as well as the possibility that key trials or new launches underperform, could quickly challenge the idea that Exelixis is still mispriced. Find out about the key risks to this Exelixis narrative.  Build Your Own Exelixis Narrative If you see the data differently or simply prefer to test your own assumptions, you can build a custom Exelixis story in just a few minutes, starting with Do it your way. A great starting point for your Exelixis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. Ready to Find Your Next Idea? If Exelixis is already on your radar, do not stop there, broaden your opportunity set with a few focused screens that can surface ideas you might otherwise miss.  Target potential mispricings by scanning these 879 undervalued stocks based on cash flows that line up with the kind of cash flow strength and balance sheet quality you like to see. Ride powerful tech trends by checking out these 28 AI penny stocks that blend real business traction with exposure to artificial intelligence themes. Lock in income ideas by reviewing these 11 dividend stocks with yields > 3% that may offer more dependable cash returns than you will find in a single stock.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Exelixis might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602530713","isCrawlerRequest":true}